Sri Kosaraju

An experienced growth company leader, Sri joined Inscripta^® as President and CEO in October 2020. Prior to that, Sri was President of Penumbra (NYSE: PEN), a global healthcare company focused on innovative therapies. Sri joined Penumbra in 2015, serving as CFO and Head of Strategy until his promotion to President in 2019. Earlier in his career, he spent 16 years at JPMorgan serving as Head of Healthcare and co-Head of Technology Equity Capital Markets working with emerging, high-growth life science and technology companies.

Sri currently serves on the Board of Directors of Inscripta^®, 10x Genomics (Nasdaq: TXG), where he is also Chair of the Audit Committee, and Nevro (NYSE: NVRO).